| Alpha emitter radium-223 and survival in metastatic prostate cancer C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ... New England Journal of Medicine 369 (3), 213-223, 2013 | 3663 | 2013 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2072 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1732 | 2017 |
| Gold nanoparticles as novel agents for cancer therapy S Jain, DG Hirst, JM O'Sullivan The British journal of radiology 85 (1010), 101-113, 2012 | 1229 | 2012 |
| Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle, D Bloomfield, ... The Lancet Oncology 17 (8), 1047-1060, 2016 | 1227 | 2016 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1068 | 2018 |
| Radiation-induced bystander signalling in cancer therapy KM Prise, JM O'sullivan Nature Reviews Cancer 9 (5), 351-360, 2009 | 893 | 2009 |
| Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind … O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ... The Lancet Oncology 15 (7), 738-746, 2014 | 552 | 2014 |
| Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies S Jain, JA Coulter, AR Hounsell, KT Butterworth, SJ McMahon, ... International Journal of Radiation Oncology* Biology* Physics 79 (2), 531-539, 2011 | 547 | 2011 |
| Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a … P Hoskin, O Sartor, JM O'Sullivan, DC Johannessen, SI Helle, J Logue, ... The Lancet Oncology 15 (12), 1397-1406, 2014 | 482 | 2014 |
| Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ... Scientific reports 1 (1), 18, 2011 | 459 | 2011 |
| Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours JM O’sullivan, RA Huddart, AR Norman, J Nicholls, DP Dearnaley, ... Annals of Oncology 14 (1), 91-96, 2003 | 419 | 2003 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 356 | 2020 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 356 | 2019 |
| Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial F Saad, J Carles, S Gillessen, A Heidenreich, D Heinrich, J Gratt, J Lévy, ... The Lancet Oncology 17 (9), 1306-1316, 2016 | 314 | 2016 |
| Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ... The Lancet 396 (10260), 1413-1421, 2020 | 287 | 2020 |
| Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy B Nugent, S Lewis, JM O'Sullivan Cochrane Database of Systematic Reviews, 2013 | 274 | 2013 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ... Annals of Oncology 29 (5), 1235-1248, 2018 | 269 | 2018 |
| Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ... Radiotherapy and Oncology 100 (3), 412-416, 2011 | 238 | 2011 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 221 | 2022 |
